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Abstract
Inhibitors of DNA binding and cell differentiation (Id) proteins are members of the large family of the helix-loop-
helix (HLH) transcription factors, but they lack any DNA-binding motif. During development, the Id proteins play a
key role in the regulation of cell-cycle progression and cell differentiation by modulating different cell-cycle
regulators both by direct and indirect mechanisms. Several Id-protein interacting partners have been identified thus
far, which belong to structurally and functionally unrelated families, including, among others, the class I and II bHLH
transcription factors, the retinoblastoma protein and related pocket proteins, the paired-box transcription factors,
and the S5a subunit of the 26 S proteasome. Although the HLH domain of the Id proteins is involved in most of
their protein-protein interaction events, additional motifs located in their N-terminal and C-terminal regions are
required for the recognition of diverse protein partners. The ability of the Id proteins to interact with structurally
different proteins is likely to arise from their conformational flexibility: indeed, these proteins contain intrinsically
disordered regions that, in the case of the HLH region, undergo folding upon self- or heteroassociation. Besides
their crucial role for cell-fate determination and cell-cycle progression during development, other important cellular
events have been related to the Id-protein expression in a number of pathologies. Dysregulated Id-protein
expression has been associated with tumor growth, vascularization, invasiveness, metastasis, chemoresistance and
stemness, as well as with various developmental defects and diseases. Herein we provide an overview on the
structural properties, mode of action, biological function and therapeutic potential of these regulatory proteins.
Keywords: Id protein, Helix-loop-helix protein, Intrinsically disordered protein, Cell-cycle regulation, Cell
differentiation, Development, Chemoresistance, Cancer stemness
Background
The helix-loop-helix (HLH) transcription factors are a
large family of proteins that share a common HLH do-
main for protein-protein interaction. They may be fur-
ther divided in seven classes (Table 1) [1–3]: class I
proteins are broadly expressed and contain an additional
basic DNA-binding motif N-terminal to the HLH do-
main, thus they are called basic-HLH (bHLH) proteins.
Examples of class I bHLH transcription factors are the E
proteins (E12, E47, HEB and E2-2, also known as tran-
scription factor 4, abbreviated as TCF-4, or immuno-
globulin transcription factor 2, abbreviated as ITF-2 [4]).
The E proteins can form DNA-binding homodimers or
heterodimers with other E proteins and class II bHLH
proteins like the tissue-specific myogenic regulatory
factors (e.g. MyoD) [5, 6]. In class III and IV proteins
the bHLH domain is C-terminally elongated, respect-
ively, with a leucine-zipper (LZ) motif [2, 7–11] and a
Per-ARNT-SIM (PAS) motif [12]. Class VI proteins con-
tain proline residues in the DNA-binding motif [2, 13, 14].
Finally, class V HLH proteins are the inhibitors of DNA
binding and cell differentiation (Id1-4) that display no
DNA-binding motif [15–17].
The HLH domain, which consists of two amphipa-
tic α-helices connected by a loop, is responsible of
the homo- or heterodimerization of the (b)HLH pro-
teins: the resulting fold is a non-covalent, parallel,
left handed four-helix bundle [5, 18]. In the case of
bHLH dimers, such fold allows the tweezers-like
juxtaposition of the two N-terminal basic helices,
which is ideal to specifically bind DNA double
strands including E-boxes (CANNTG) [19–21], N-
boxes (CACNAG) [14], and Ets sites (GGAA/T) [22]
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(Fig. 1). Formation of the ternary complex
DNA[bHLH(−LZ)]2 triggers transcriptional activa-
tion. This, however, does not occur for class V pro-
teins, as they lack the DNA-binding motif: as a
result, these proteins may sequester class I and II
bHLH proteins in non-DNA-binding dimers, thus
acting as negative regulators of bHLH-mediated gene
expression [15, 23].
This review will focus on the class V Id proteins, with
the aim to give an overview of them, discussing the fol-
lowing aspects: (i) structural features, (ii) mode of ac-
tion, (iii) biological function in physiological as well as
pathological scenarios, and (iv) potential role in tumor
therapy.
Structural features
The Id1 protein was first identified in 1990 by Benezra
et al. [15]. Since then four mammalian Id proteins, Id1-4
[24–26], as well as Drosophila [27] and Xenopus [28]
homolog proteins have been identified. In humans the
four Id genes are located on chromosomes 20q11 (Id1)
[29, 30], 2p25 (Id2) [29], 1p36.1 (Id3) [31, 32], and 6p21-
p22 (Id4) [33]. For mouse, rat and human Id1 [30, 34–38]
as well as for rat and human Id3 [39, 40] a spliced form has
been also detected, which differs from the canonical one
only in the C-terminal domain (Fig. 2b): for example, the
canonical and spliced forms of human Id1 are 155- and
149-residue long and differ from position 143 [30, 36, 38].
The canonical and spliced forms of human Id3 are
Table 1 Class I-VII of the HLH transcription factors
Class Structural
domain
Representative members Properties and function
I bHLH E-protein family (E12, E47, E2-2/TCF-4/ITF-2, HEB) [1–3, 333] Broadly expressed; Self- or heteroassociation with class II proteins;
Regulation of neuro-, myo-, lymphogenesis
II bHLH Myogenic regulatory factors (MyoD, myogenin, Mrf4, Myf-
5,6) [6]; NeuroD/Beta2 [334]; Mash-1 [335, 336], d/e-HAND
[337]; Twist [338]
Tissue-specific; Heteroassociation with class I proteins; Regulation of
myogenesis (myogenic regulatory factors), islet cells differentiation
(NeuroD/Beta2), neurogenesis (Mash-1), cardiac morphogenesis (d/
e-HAND), and mesoderm development (Twist)
III bHLH-LZ MiT family (MiTF, TFE3, TFEB, TFEC) [9, 10]; Myc [8] Melanocytes maturation (MiTF), B cells activation (TFE3), placental
vascularization (TFEB), osteoclast development (MiTF, TFE3, TFEC),
cell proliferation/differentiation, oncogenesis and apoptosis (Myc)
IV bHLH-LZ Mad family (Mad1/3/4, Mxi1) [339–341], Max [7, 342] Homodimerization or heterodimerization with Myc; Regulation of
cell proliferation
V HLH Id proteins (Id1-4) [16, 17, 24, 343] Heterodimerization with class I and, to a minor extent, class II
proteins; Regulation of cell proliferation/differentiation during
development and in cancer
VI b(Pro)HLH HES family (HES1-7) [13] Regulation of cell proliferation/differentiation during embryogenesis
VII bHLH-PAS AhR, HIFα, SIM, ARNT [12] Regulation of xenobiotic (AhR/ARNT) and hypoxic (HIFα/ARNT)
response genes, and of neural development (SIM/ARNT)
Fig. 1 Control of DNA transcription by positive and negative HLH regulators. a Broadly expressed bHLH E proteins build heterodimers with
tissue-specific bHLH proteins, which results in DNA binding at specific DNA sequences (in red) and DNA-transcription activation. b E-
protein association with the Id proteins results in dimers with no ability to bind the DNA because the Id-protein subunit lacks the DNA
binding region, which leads to inhibition of DNA-transcription activation. The helices of the HLH domains are represented by cylinders
(grey for class I bHLH, orange for class II bHLH and magenta for Id); a blue-colored cylinder represents the basic DNA-binding region of
the bHLH domain
Roschger and Cabrele Cell Communication and Signaling  (2017) 15:7 Page 2 of 26
119- and 160-residue long and differ from position
101 [39]. Interestingly, the spliced form of Id1 has
much higher propensity to homodimerize than the ca-
nonical form [37]. Instead, the spliced form of Id3
seems to have less affinity for the bHLH E protein
E47 than the canonical form [39].
Sequence alignment of the four Id proteins reveals that
the HLH domain is highly conserved, especially within
the two helical motifs (helix-1 and helix-2) and at their
junctions with the loop (Fig. 2c). Accordingly, the Id
HLH region badly tolerates sequence modifications,
resulting in altered conformation [41–44] and function
[45]. Contrarily to the highly conserved HLH domain,
the N-terminal and C-terminal domains are unique for
each of the Id proteins, being different both in length
and amino-acid sequence (Fig. 2a, b). Nevertheless, some
common features can be found also in these regions: for
example, Id1-4 possess a phosphorylation site at Ser-5
[46–49], and Id1,2,4 display a C-terminal destruction
box (D-box) that triggers protein degradation via the
anaphase-promoting complex/cyclosome Apc/C and its
activator Cdh1 (Apc/CCdh1) [50]. Instead, only Id2 con-
tains a nuclear export signal (NES) that is recognized by
the nuclear export receptor CRMP1 [51].
The HLH and flanking regions display different struc-
tural properties: indeed, the Id HLH domain undergoes
self- (Id2 [52], Id3 [53, 54]) or heteroassociation with the
HLH domains of class I and II proteins and folds into a
four-helix bundle, as shown by the crystal structure of the
Id2 HLH domain (PDB ID: 4AYA) [55] and by the solu-
tion NMR structure of the Id3 HLH domain (PDB ID:
2LFH) [56] (Fig. 2d). In contrast, the N-terminal and C-
terminal domains are mainly disordered, as suggested by
disorder probability prediction analysis [57–59] as well as
Fig. 2 Amino-acid sequences of the N-terminal (a) and C-terminal domains (b) as well as of the HLH domains (c) of the human Id proteins (for
Id1 and Id3 the C-terminus found in a spliced form is reported as Id1′ and Id3L). d Structures of the homodimers of the fragments Id2 30–82 [55]
and Id3 29–83 [56]. D-box, destruction box; NES, nuclear export signal (UniProtKB: P41134-1 for Id1, P41134-2 for Id1′, Q02363 for Id2, Q02535 for
Id3, P47928 for Id4. GenPept: S71405 GI: 2135331 for Id3L)
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by conformational data on synthetic peptides reproducing
the N-terminal and C-terminal regions of the Id proteins
[42, 43]. Therefore, the Id proteins contain intrinsically
disordered regions that, in the case of the HLH re-
gion, undergo folding upon self- or heteroassociation
[41, 44, 53, 55, 56]. A common feature of intrinsically
disordered proteins is the high propensity to aggregate and
precipitate, which represents the major obstacle for the
structural investigation of these proteins. Indeed, attempts
to grow crystals of the full-length Id2 protein failed thus
far [60], and only N-terminal and C-terminally truncated
Id2 (residues 30–82) was successfully crystallized [55].
Despite the lack of a well-defined structure, the N-
terminal and C-terminal domains are certainly important
for the biology of the Id proteins, as supported by the
presence of regulatory signals there, including ubiquitina-
tion, phosphorylation and molecular recognition elements
like NES and D-box, which will be discussed in the follow-
ing. In addition to the primary structure and its post-
translational modifications, it is highly probable that also
the conformational dynamics of the flexible regions will
play a role in protein-protein interaction events.
Mode of action
The Id proteins perform their biological function via
protein-protein interactions that involve not only class I
and II bHLH proteins [61–63], but also proteins belong-
ing to other families and containing other types of do-
mains. These include the retinoblastoma protein tumor
suppressor (pRb) and related pocket proteins [64, 65], the
actin-associated protein enigma homolog (ENH) [66, 67],
the p200 family member p204 [68, 69], Ets-domain pro-
teins [70], MIDA1 [71, 72], Pax transcription factors [73],
adenovirus E1A proteins [74], ADD1/SREBP-1c [75], the
C8 subunit of the 20 S proteasome [76], the hepatitis B
virus-encoded protein X (HBX) [76], the S5a subunit of
the 26 S proteasome [77], the COP9 signalosome (CSN)
subunits CSN5 and CSN7 [78], the deubiquitinase USP1
[79], the Apc/C subunits Apc1, Apc5, Apc8/Cdc23 [50],
the cell-membrane protein caveolin-1 [80], the four-and-
a-half LIM-only protein 2 (FHL2) [81], the Von-Hippel
Lindau(VHL)-elongin-C complex [82], and the estrogen
receptor beta-1 (ERβ1) [83] (Table 2). The fact that some
of these interactions are specific for individual Id-family
members suggests that they are not only mediated by the
highly conserved HLH motif, but also by the less con-
served N-terminal and C-terminal regions. For example,
the interaction of Id2 with the VHL-elongin-C complex is
suggested to occur in a short region of the Id2 N-terminal
domain, which contains Thr-27: however, Dyrk1-mediated
phosphorylation of Thr-27 prevents the interaction with
the protein complex [82].
Interestingly, the presence of the unique polyalanine
segment within the N-terminus of Id4 seems to
positively affect the HLH-mediated interaction of the
Id4 protein with the other Id proteins [63], an observa-
tion that further underlines the structural and functional
importance of the N-terminal and C-terminal domains
of the Id proteins.
Regulation
For the correct function of a protein in the cell, its ex-
pression, localization, and degradation must be strictly
timely regulated. The following subsections report on
the known mechanisms that regulate the Id-protein
activity.
Gene expression
Usually, Id gene expression is positively regulated in un-
differentiated, highly proliferative, embryonic or cancer
cells [16, 84–91] (Fig. 3). For example, during develop-
ment the Id gene expression is activated in stem and
progenitor cells to support proliferation and inhibit dif-
ferentiation, whereas it is repressed upon lineage com-
mitment and differentiation [1, 92]. Recently, it has been
shown that the Id1-3 genes are targets of the nuclear
factor Y (NFY) complex (NFYa-c) that binds the
CCAAT box on their promoters (in contrast, the Id4
gene lacks the CCAAT box) [93]: accordingly, NFY in-
corporation into the Id1-3 gene promoters decreases
upon induction of differentiation with retinoic acid of
the human embryonic carcinoma cell line NTera2,
which is a valuable cell model to study the expression
profile during development. This is due to the loss of
NFYc at the protein level in the differentiating cells,
which results in Id1-3 genes down-regulation. Interest-
ingly, also the epigenetic markers for gene transcription
(histone 3 Lys-9 acetyl, H3K9ac) and repression (histone
3 Lys-9 dimethyl, H3K9me2) incorporated into the Id1-3
gene promoters respectively decrease and increase dur-
ing differentiation. However, after 7 days of differenti-
ation the positive regulators NFYc and H3K9ac recover
with consequent increase in Id1-3 gene expression that
is required for cellular growth [93].
In primary immature thymocytes the Id3 gene ex-
pression is activated by the Egr1 transcription factor
that is a downstream target of the TCR-mediated acti-
vation of the RAS-ERK-MAPK pathway, which pro-
motes thymocyte maturation upon inhibition of the E
proteins [84, 94].
In vitro, treatment of cells with serum or platelet-
derived growth factor (PDGF) induces Id gene expres-
sion [95] (serum-induced expression of Id1 is linked to
the serum-dependent protein complex including the
Egr1 protein [96]). Also the sex hormone estradiol posi-
tively affects Id1 gene expression in human breast cancer
cells, which, however, may be counteracted by progester-
one [97]. Id1 and Id3 gene expression can be stimulated
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Table 2 Protein-protein interactions involving Id proteins
Id protein Protein partner Description References
Id1-4 Class I and II bHLH proteins Dominant negative regulation of bHLH factors [61–63, 236]
Id2 pRb and related pocket proteins p107 and p130 Inhibition of pRb-mediated cell-cycle arrest
(as no interaction between the pRb small pocket
and Id2 was detected by mass spectrometry
and NMR spectroscopy [136], a multiprotein
complex is likely to be formed)
[64, 65]
Id2 ENH Id-protein localization in the cytoplasm by
association of the Id2 HLH and ENH LIM domains
[66, 67]
Id1-3 p204 Id-protein localization in the cytoplasm [68, 69]
Id1-3 Ets-domain proteins Elk-1 and SAP-1/-2 Inhibition of the winged-helix-turn-helix
transcription factors regulating the expression
of immediate-early response genes such as
c-Fos and Egr1
[70]
Id1 MIDA1 Inhibition of MIDA1-Z-DNA interaction with
stimulation of cell growth and inhibition
of neural differentiation
[71, 72, 344, 345]
Id1-3 Pax-2/-5/-8 Inhibition of the paired-box transcription
factors involved in development
[73]
Id1, Id2 Adenovirus E1A protein Induction of apoptosis in cells expressing p53 mutants [74]
Id2, Id3 ADD1/SREBP-1c Inhibition of the bHLH-LZ transcription factor
that regulates the expression of adipocyte genes
[75]
Id1 C8, HBX Induction of proteasome-mediated HBX degradation [76]
Id1 S5a Suppression of the Id-protein activity [77]
Id1, Id3 CSN5 (Id1, Id3), CSN7 (Id3) Suppression of Id-protein ubiquitination
by CSN-mediated phosphorylation
[78]
Id1-3 USP1 Id-protein deubiquitination [79]
Id2 Apc/C subunits Apc1, Apc5, Apc8/Cdc23 Id2-protein degradation [50]
Id1 Caveolin-1 Induction of cell migration and chemotherapy
resistance in prostate cancer
[80]
Id1-4 FHL2 Antagonism of the inhibitory effect of the Id
proteins on E47-mediated transcription
[81]
Id2 VHL-elongin-C Inhibition of ubiquitination and degradation of HIF2α [82]
Id1 ERβ1 Inhibition of cell proliferation and p21 up-regulation [83]
Serum, PDGF [95,96] 
Retinoic acid (epithelial cells) [98]
(B-lymphocyte progenitors and mature B-cells) [100,101]
Egr1 (immature thymocytes) [84,94]
Egr2 (osteoclasts precursors) [184]
BMP2 (myoblasts, osteoblast-like cells) [102-104]
NFY (embryonic cells) [93]
Activin A (epithelial cells) [99]
/Smad3/ATF3 (epithelial cells) [108]
TGF
TGF
TNF /p38/ATF3 (epithelial cells) [108]




Myc (neuroblastoma, breast cancer) [115,116]
BMPs (multiple myeloma, breast and lung cancer) [105-107,113]
Estradiol (breast cancer) [97]
p53 mutants (breast cancer) [111]
TGFβ
β-catenin/TCF (colon adenocarcinoma) [114] 
Stat3 (colorectal cancer) [120]
Nicotine (non-small cell lung cancer) [117]
EGF (non-small cell lung cancer) [117]
Bcl-3 (prostate cancer) [118]
FLT3-ITD (acute myeloid lymphoma) [119]
BCR-ABL (acute myeloid lymphoma) [119]
Progesterone (breast cancer) [97]
Cancer 
Id 
Fig. 3 Selected molecules/pathways involved in the regulation of Id gene expression in normal development and cancer
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by retinoic acid in keratinocytes [98]. In contrast, the cy-
tokines activin-A and TGFβ1 lead to suppression of Id1,
Id2 and Id3 gene expression in keratinocytes [99].
However, TGFβ1 has been shown to induce Id3 gene
expression in B-lymphocyte progenitors, resulting in
inhibition of their growth and survival [100], as well
as Id2 gene expression in mature B cells, preventing
IgE class switching [101]. Bone morphogenic protein
2 (BMP2), another cytokine from the TGFβ family,
positively affects Id1 gene expression in myoblasts
[102, 103], osteoblast-like cells [104], breast [105] and
lung [106, 107] cancer cells. In epithelial cell lines,
the BMP2-mediated Id1 gene expression may be
counteracted by the TGFβ/Smad3 or TNFα/p38 path-
ways that activate the stress response factor and tran-
scriptional repressor ATF3 [108]. Instead, TGFβ does
not induce ATF3 in glioblastoma multiforme, which
turns the TGFβ-mediated transcription of Id1 from
repression to activation [109]. In glioblastoma cells
Id1 expression is also PI3K-dependent through the
phosphorylation of 4E-BP1 via Akt-mTORC1 or Akt-
PPM1G. Increase in the phosphorylation state of 4E-
BP1 results in the activation of Id1 translation,
leading to increased Id1 expression and glioblastoma
malignancy [110].
Mutations of p53 have been shown to positively regu-
late the transcription of the Id4 gene in breast cancers:
indeed, complexes of p53 mutants and E2F1 bind to the
Id4 promoter and activate Id4 expression [111]. Instead,
Id2 expression is down-regulated by the transcriprional
repressor p53 in neural progenitor cells [112].
In multiple myeloma the Id1 and Id2 gene expression
is induced by over-expressed BMPs, which supports cell
proliferation [113]. In colon adenocarcinoma the Id2
gene is a target of the β-catenin/T-cell factor transcrip-
tion pathway and induces the clonogenic growth of the
colon cells [114]. In neuroblastoma the Id2 gene is acti-
vated by Myc oncoproteins, which leads to the inhibition
of the pRb tumor suppressor pathway with consequent
cell-cycle progression [115]. In breast cancer Myc up-
regulates Id3 that supports the entry in the S-phase by
enhancing the cyclin/Cdk activity [116]. In non-small
cell lung cancer the activation of the Id1 gene promoter
can be induced by nicotine and EGF in a Src-dependent
manner, which leads to the down-regulation of ZBP-89,
a zinc finger transcriptional repressor of the mesenchy-
mal markers fibronectin and vimentin [117]. In prostate
cancer the over-expression of B-cell leukemia 3 (Bcl3)
protein is correlated with the expression of Id1 and Id2,
which is in turn accompanied with resistance to pro-
apoptotic drugs [118]. In acute myeloid leukemia Id1
has been shown to be a target of the oncogenic tyrosine
kinases FLT3-ITD and BCR-ABL, which results in pro-
tection of the cells against TRAIL-induced apoptosis
[119]. In colorectal cancer Stat3 mediates the transcrip-
tional activation of the Id1 gene, which correlates with
p53 inactivation [120].
Phosphorylation
Id2 and Id3 may be phosphorylated at Ser-5 by Cdk2 at
the G1-S transition [46–48, 121–123] (Fig. 4). Phosphor-
ylated Id2 accumulates in the nucleus and seems to be
Fig. 4 Phosphorylation of Id2 and Id3. These proteins are phosphorylated by Cdk2 at the G1-S transition [46–48, 121–123] (a). Phosphorylated Id2
(or its S5D mimic) accumulates in the nucleus, whereas phosphoablated Id2 (S5A) accumulates in the cytoplasm and induces cell-cycle arrest or
apoptosis [121, 122] (b). Phosphorylated Id3 induces cell-cycle progression of VSMCs via inhibiting the cell-cycle blocker p21Cip1 at the transcriptional
level [123] (c). Phosphorylated Id2 is less resistant to degradation than unphosphorylated Id2. In glioblastoma high Id2 levels can be maintained by
PP2A activity (d) [124]
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key player in cell-cycle regulation, as the phosphoablated
mutant (Ser-5-Ala-Id2) induces apoptosis of myoblasts
[121] and mammary epithelial cells [122], as well as it
inhibits the entry in the S-phase of vascular smooth-
muscle cells (VSMCs) [123]. Also Id3 phosphorylation is
important for VSMCs proliferation: it has been proposed
that phosphorylation of Id3 at the G1-S transition con-
tributes to suppress the Cdk2- and cell-cycle-blocker
p21Cip1 in the early G1 phase, further supporting the
linkage between Id3 phosphorylation and cell-cycle pro-
gression [47]. The negative effect of Id3 phosphorylation
on the p21Cip1 levels is probably due to enhanced ability
of the phosphoprotein to inhibit transcriptional activa-
tion of p21Cip1 in comparison to the phosphoablated
(Ser-5-Ala-Id3) and non-phosphorylated protein, an
assumption that may be justified by the observation that
Ser-5 phosphorylation seems to affect the protein-
protein interaction properties of Id3 (as well as of Id2),
at least with respect to the class I bHLH proteins
[46–48].
In neural precursor cells the N-terminal Id2 phosphor-
ylation regulates the expression level of the protein: in-
deed, a phosphoablated mutant appears to be protected
against proteasome-dependent degradation, thus pro-
moting proliferation. Moreover, the phosphatase PP2A
has been shown to maintain high Id2 levels in glioblast-
oma: in contrast, inhibition of selected PP2A subunits in
glioblastoma-derived stem cells (GSCs) decreases Id2
levels as the result of regained protein phosphorylation
and enhanced degradation [124].
Unlike Id2 and Id3, Id1 has been found to be phos-
phorylated at Ser-5 by PKA, which apparently blocks the
nuclear export of the protein [49].
Degradation
The Id proteins are short-living proteins with half-
lives shorter than one hour [125, 126]. The proteins
Id1-3 are degraded via the 26 S proteasome pathway
upon N-terminal ubiquitination, whereas Id4 degrad-
ation is dependent from the E1 enzyme [125].
Proteasome-mediated degradation of Id1 and Id3 is
negatively regulated by the COP9 signalosome (CSN)
that directly interacts with the proteins and induces
their phosphorylation [78]. Moreover, the deubiquiti-
nase USP1 can associate with and deubiquitinate Id1-
3 in mesenchymal stem cells, thus preserving their
stem cell state [79]. Also the interaction of the Id
proteins with their bHLH binding partners protects
them from fast degradation [125–127]. In contrast,
degradation of Id1, Id2 and Id4 is triggered by Apc/
CCdh1 that recognizes the destruction box (D-box)
motif, RXXLXXXN, located C-terminally of the HLH
domain (Table 3) [50].
Subcellular localization
The Id proteins may be found both in the nucleus and
in the cytoplasm [128], and their nucleo-cytoplasmic dis-
tribution is regulated either by passive diffusion, due to
their small size (13–18 kDa), or by nuclear localization/
export signals (NLS/NES) embedded in their sequences,
which regulate the nucleo-cytoplasmic shuttling by bind-
ing nuclear pore complexes (Table 3). Id1 [129] and Id2
[51] contain a NES motif in the HLH domain and in the
C-terminus, respectively. Although the Id proteins lack
canonical NLS motifs, it is likely that the basic residues
present in the HLH domain fulfill the task of nuclear
localization, as it has been shown for Id1 [126]. How-
ever, in the case of Id3, which lacks the basic-residue
pattern shown by Id1 and Id2, the HLH domain seems
to be enough for nuclear localization: indeed, Id3 has
been shown to accumulate in the nucleus or in the cyto-
plasm upon co-expression with or in the absence of
bHLH E47, respectively [127]. This suggests that the
bHLH protein, which contains its own NLS, my act as a
carrier of the Id protein into the nucleus. The
localization of Id2 in the cytoplasm may be positively
regulated by the cytoplasmic protein ENH that is able to
interact with the Id2 protein and to retain it in the cyto-
plasm: the Id2 HLH domain and at least one of the three
LIM domains of ENH mediate the interaction between
the two proteins [66].
Cell-cycle regulation
The Id proteins contribute to the regulation of the cell
cycle in the G1 phase, mainly by antagonizing the tran-
scriptional activation of differentiation-associated genes
like the Cdk inhibitors p15, p16 and p21 mediated by
the class I bHLH proteins [130] and Ets-domain proteins
Table 3 D-box and NLS/NES motifs of the Id proteins











The D-box motifs are recognized by Apc/CCdh1 and trigger Id-protein degradation.
The characteristic D-box amino-acid positions are in bold [50]. The NLS/
NES motifs regulate the Id-protein nucleo-cytoplasmic shuttling [51, 126,
129]. The hydrophobic residues important for the nuclear export are in
bold. The conserved basic positions in the NLS motifs are in bold
Roschger and Cabrele Cell Communication and Signaling  (2017) 15:7 Page 7 of 26
[131], promoting cell-cycle progression [132–134] or
inhibiting cell senescence [135] (Fig. 5).
Besides Cdk inhibitors, the Id proteins affect also other
cell-cycle regulators, including pRb and p53. Id2, but
not the other Id proteins, has been shown to interact
with the hypophosphorylated, active form of pRb and
with the pRb-related pocket proteins p107 and p130,
which abrogates their cell-cyle arrest activity [64, 65].
The mode of interaction between pRb and Id2 is not
fully understood and, probably, it includes a multido-
main interaction, since the small pocket domain of pRb
is not able to bind Id2 in vitro [136]. Unlike Id2 that af-
fects the pRb pathway by physically interacting with the
members of the pRb family, Id1 and Id3 are likely to in-
directly regulate the pRb activity by binding to Ets-
domain proteins [70] or class I bHLH proteins [130] and
thus decreasing the expression of p16 [131, 135, 137] or
p21 [138], potent inhibitors of the cyclin/Cdk complexes
that mediate pRb phosphorylation. Hyperphosphorylated
pRb is no longer able to bind the transcription factors
E2F1-3 that, thus, activate cell division and may trigger
tumorigenesis [139].
Id1 is able to impair the p53-mediated response to
DNA damage, which has been attributed to the negative
effect of Id1 on p21 expression; in contrary, p53 up-
regulates the bHLH transcription factor DEC1 that, in
turn, down-regulates Id1 [138]. This indicates a cross
talk between p53 and Id1, which regulates cell-cycle ar-
rest and senescence versus cell-cycle progression.
Id-protein induced cell proliferation has been also cor-
related to activation of the MAPK (mitogen-activated
protein kinase) signaling pathway [140]. Indeed, Id1 pro-
motes not only phosphorylation of Raf and MEK1/2,
which are key regulators of the MAPK pathway, but also
Egr1 expression, which is a downstream effector of the
activated MAPK pathway and, in turn, activates the tran-
scription of the Id1 gene [96]. This suggests that Id1 is
not only a positive upstream regulator but also a down-
stream target of the MAPK signaling pathway [96, 140].
Also the Id3 gene is a downstream target of Egr1 upon
TCR activation of the ERK MAPK pathway [94].
Id proteins in developmental processes and
disorders
The Id proteins play a key role during development
[16, 86, 91, 141]. Based on Id gene knockout animal
models, single knockout leads to developmental de-
fects of different entity, depending on the lacking Id
gene [142–148] (Table 4). Instead, the double knock-
out of Id1 and Id3 leads to embryonic lethality [149].
This suggests that Id3 can compensate loss of Id1
during embryonic development.
Neural processes
Id1 and Id3 are highly expressed in the early stages of
the central nervous system, whereas their levels decrease
in the late stages [150–152], which suggests a role of
these proteins in stimulating neural precursor cells pro-
liferation while inhibiting differentiation. In the case of
Id2 and Id4, their expression is retained also in adult-
hood [88, 153, 154].
During neural development Id2, E47 and pRb contribute
to the regulation of the cell cycle mainly by controlling
Fig. 5 The Id proteins promote cell-cycle progression. Cyclin/Cdk-
mediated cell-cycle progression is supported by the Id-protein-
induced inactivation of the Cdk inhibitors p15/16/21 and Ets, or by
the direct interaction of Id2 with hypophosphorylated pRb. In
addition, a cross talk between Id1 and the p53 pathway involving
the cell-cycle blocker p21 and the Id1 transcriptional repressor DEC1
has been proposed. Also, Id1 may activate the MAPK pathway by
promoting the phosphorylation of Raf and MEK1/2, which results in
the induction of the transcription factor Egr1, a positive regulator of
Id1 and Id3 gene expression
Table 4 Id gene knockout studies in mice
Deleted gene Phenotype
Id1−/− Decreased neovascularization [146]
Id2−/− Lack of Langerhans and splenic dendritic
cells, reduced number of NK cells, altered
peripheral lymphoid organs [143, 147]
Id3−/− Defects in B-cell activation and proliferation
upon B-cell receptor signaling, and in both
negative and positive selection of T-lineage
progenitors [144, 145]
Id4−/− Altered brain size, defects in forebrain
development [142, 148]
Id1−/−, Id3−/− Embryonic lethality with cranial hemorrhage,
small brain size, premature neural differentiation [149]
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the Cdk inhibitor p57Kip2, which is essential for cell-cycle
arrest and differentiation. The transcription of p57Kip2 is
activated by E47 and indirectly repressed by Id2, which in-
hibits E47. However, pRb may counteract the inhibitory
activity of Id2. Therefore, it has been suggested that
p57Kip2 acts as proliferation checkpoint during brain de-
velopment. However, this checkpoint may be override by
up-regulated Id2 leading to hyper-proliferation and devel-
opment of neuroblastoma [155].
Also p53 plays an important role in maintaining nor-
mal neural progenitor cells (NPCs) proliferation, and it
acts as repressor of Id2 gene expression by binding a
conserved site within its promoter. In contrast, mutated
p53 in glioma is associated to elevated Id2 expression
and thus to increased proliferation and self-renewal of
glioma stem-like cells [112].
Id2 and Id4 play a crucial role in regulating the glio-
blastoma multiforme (GBM) stem-like cells differenti-
ation, thus reducing their cancer initiating potential.
Indeed, upon induction of differentiation with histone
deacetylase inhibitors, Id2 and Id4 are up-regulated and
promote neuronal/astroglial differentiation at the ex-
pense of oligodendroglial differentiation by antagonizing
the oligodendroglial lineage-associated transcription fac-
tors (Olig) 1 and 2 at the transcriptional level [156].
Because of the important role of the Id proteins in
neural development [157], their deregulation may not
only be implicated in tumor formation but also in neu-
rodevelpmental disorders. For example, as Id2 and Id4
inhibit oligodendroglia differentiation [62], which is re-
quired for remyelination, they might have a role in mul-
tiple sclerosis that is characterized by axonal
demyelination [158, 159]. Furthermore, the Id proteins
might be involved in the Rett-syndrome (RTT): indeed,
the Id gene transcriptional repressor MECP2 is mutated
in RTT, which leads to overexpression of the Id proteins
and altered neuronal maturation [160].
Traumatic brain injury leads to enhanced BMP2 and
Id3 expression in the stem cells niche of the subventri-
cular zone. Id3, in turn, inhibits the bHLH-mediated
transcriptional repression of various astrocyte-specific
genes. This leads to the differentiation of neural stem/
precursor cells into astrocytes [161].
Immune system-related processes
The class I bHLH proteins E12, E47 and HEB, and the
Id proteins are major players in B-cell and T-cell devel-
opment [162–166]. For example, the Id proteins are
highly expressed in progenitor B-cells, whereas they de-
crease during differentiation to pre-B cells and mature
B-cells, which inversely correlates with bHLH activity
[165]. Additionally, Id2 enhances erythroid development
by affecting the activity of the Ets-domain protein PU.1,
a regulator of erythromyeloid development, and of the
zinc-finger protein GATA-1: Id2 is able to interact with
PU.1 and prevent the PU.1-GATA-1 interaction, thus
initiating the myeloid versus erythroid program [167].
Recently, Id3 has been correlated to the TGFβ- and
interleukin (IL4)-mediated signaling that controls the
differentiation of CD4+ IL9 producing helper T (TH9)
cells. Indeed, TGFβ1 and IL4 act as Id3 transcriptional
repressors, which results in E-protein- and GATA-3-
mediated activation of the IL9 gene transcription and
even in enhanced anti-tumor response of the T cells in a
melanoma mouse model [168].
The Id proteins are not only crucial for the proper
development of the immune system, but they are also
involved in immune response and may play an im-
portant role in regulating immunoglobulin gene ex-
pression. Indeed, the Id proteins have been found to
inhibit immunoglobulin class switch recombination
(CSR) to IgE in activated B-cells in response to
TGFβ1 [101, 163, 169], which suggests a protective
role of the Id proteins to prevent harmful immune
reactions like allergic hypersensitivity. Moreover, Id2
is up-regulated in CD8+ T-cells as well as in memory
CD8+ T-cells during infection, whereas Id2-deficient
CD8+ T-cells show altered expression of genes influ-
encing survival as well as impaired memory formation
in response to infection [170]. Also, loss of Id2 in T-
cells during influenza virus infection and in a model
of acute graft-versus-host disease (GVHD) has been
shown to increase IL10 levels [171]. This suggests
that the Id proteins play a role in regulating survival
of mature T-cells.
Then, TGFβ- or IL6-mediated up-regulation of Id1 in
bone-marrow-derived myeloid cells has been shown to
induce immunosuppression during tumor progression
by inhibiting myeloid differentiation, while inducing
pathologically activated immature cells, like myeloid-
derived suppressor cells, and regulatory T-cells [172].
This shows that Id1 plays a role in tumor-induced
immunosuppression.
Mammary gland development and disorders
Mammary epithelial cells are characterized by decreased
Id1-protein expression upon treatment with differenti-
ation signals, whereas they start to proliferate upon con-
stitutive Id1 expression [173]. Unlike Id1, Id2 has been
found to be highly expressed in differentiated mammary
epithelial cells [174]. Instead, Id2 deficiency leads to im-
paired proliferation and survival of mammary epithelial
cells and to defects in alveologenesis in pregnant mice,
resulting in lactation defect [175]. During mammary
gland development Id4 expression suppresses p38MAPK
activation, thus promoting cell proliferation and prevent-
ing apoptosis [176].
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Skin development and disorders
The Id proteins regulate keratinocyte proliferation and
differentiation. Id1, Id2, and Id3 are expressed in prolif-
erating human primary keratinocytes, but they are
down-regulated upon induction of differentiation [177].
In contrast, the Id proteins are further expressed in
squamous cell carcinoma 9 (SCC9) and HaCaT cells also
upon treatment with differentiation stimuli, as well as in
SCC sections with poor up to high differentiation [177].
However, in the case of Id3 it has been reported that this
protein induces apoptosis of SCC cells through Elk-1-
mediated caspase-3/-8 activation. A truncated variant of
Id3 lacking the N-terminus is even a stronger inducer of
apoptosis, probably because of the loss of the Cdk2 Ser-
5 phosphorylation site, which abolishes Cdk2 regulation
of the Id3 function [178]. This observation has led to the
question, whether Id3 might play a tumor suppressor
role in SCC.
Up-regulation of Id1 has been observed upon skin injury
[179] and in psoriatic skin [180], which favors cell migra-
tion and proliferation. However, Id-protein expression is
down-regulated during wound repair, which is induced by
activin, a member of the TGFβ family involved in skin
morphogenesis and wound healing [99].
Bone formation
The Id proteins are important for the regulation of
osteoblast differentiation of mesenchymal stem cells and
bone-matrix formation, which is mediated by BMP2/6/9.
Indeed, the Id proteins promote the proliferation of early
osteoblast progenitor cells upon BMP9 stimulation,
however, they are down-regulated during the terminal
differentiation of committed osteoblasts [181].
In the case of osteoclast differentiation the Id proteins
are down-regulated by the TNF-related activation-
induced cytokine TRANCE that induces osteoclast
formation from monocytes/macrophages via different
transcription factors, including the bHLH Mi transcrip-
tion factor (MiTF): the latter may bind the promoter of
the osteoclast-associated receptor OSCAR, whereas it
may be inhibited upon sequestration by the Id proteins
[182, 183]. RANKL-mediated osteoclastogenesis may
be inhibited by Egr2, which is a positive regulator of the
Id genes, whereas Egr2 knockdown decreases Id2
expression, thus enhancing osteoclastogenesis [184].
Myogenesis
In the course of myogenesis, myoblasts are differentiated
into myotubes. This process is regulated by the highly
coordinated interplay of the myogenic regulatory factors
MyoD, Myf-5/-6, myogenin, and Mrf4 (class II bHLH
proteins) and their binding partners, the class I E pro-
teins and the class V Id proteins. The transcription of
muscle-specific target genes is activated by heterodimers
formed between the myogenic regulatory factors and the
E proteins. Id1, Id2 and Id3 prevent skeletal muscle dif-
ferentiation by sequestering the E proteins, thus blocking
the activity of MyoD and other myogenic bHLH proteins
[15, 185]. This inhibition is overcome by p204, a p200
protein family member that binds the Id proteins and
also triggers a decrease in their level, presumably by
shuttling them from the nucleus to the cytoplasm and
thus accelerating their degradation [68, 69]. Indeed, it
has been reported that in proliferating C2C12 myo-
blasts MyoD and Id1 are co-localized in the nucleus,
while in differentiated myotubes MyoD is located in
the nucleus and Id1 in the cytoplasm [186]. Further-
more, it has been observed, that Id2 reduces the
myogenic markers MyoD and myogenin in myoblasts,
however, ENH1 overexpression restores myogenic dif-
ferentiation by binding Id2 [67].
Angiogenesis
The formation of new blood vessels out of preexisting
ones, so called angiogenesis, is an important process
during development and wound healing. First evidence
of a role of the Id proteins in angiogenesis has been pro-
vided by a study on Id1/Id3 double knockout mice em-
bryos that died due to hemorrhage in the forebrain and
absence of blood vessels in the neuroectoderm. Interest-
ingly, already a partial reduction of the Id levels in adult
mice may reduce vascularization, growth and metastasis
of tumor xenografts [149].
Thrombospondin-1 (TSP-1) has been identified as a
target gene for Id1-mediated transcriptional repression
[146]. TSP-1 is a glycoprotein known to be a potent in-
hibitor of in vivo neovascularization and tumorigenesis.
In contrast, Id1 promotes these two events by inhibiting
the transcription of the TSP-1 gene via a yet unknown
mechanism.
Another key player in angiogenic events is the vascular
endothelial growth factor (VEGF): loss of Id1 function
has been shown to inhibit basic fibroblast growth factor-
and VEGF-induced angiogenesis [146, 149].
Granulopoiesis
Granulopoeisis is the differentiation of primitive blood
precursors into granulocytes primarily within the bone
marrow. It has been shown that Id1 is up-regulated dur-
ing early granulopoiesis and down-regulated during final
maturation. In contrast, Id2 is up-regulated in terminally
differentiated granulocytes. Constitutive expression of
Id1 or Id2 in CD34(+) cells leads to different responses,
indicating a different role of the two proteins in granulo-
poiesis: Id1 inhibits eosinophil development while
enhancing neutrophil differentiation, whereas Id2
promotes final maturation of both eosinophils and
neutrophils [187].
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Stem cells
Stem cells are mother cells that have the potential to
differentiate into any specialized cell type in the body.
They are able to self-renew or multiply; additionally,
they play an important role in development and in
the repair system of adult organisms. The Id proteins
are expressed by embryonic and somatic stem cells,
and initiate stemness by enhancing proliferation and
inhibiting differentiation [188–191]. For example Id1
sustains the hematopoietic stem cell (HSC) self-
renewal by inhibition of differentiation and keeping
the undifferentiated state [188]. Moreover, in vitro
Id1, Id2, and Id3 have been shown to increase the
self-renewal and proliferation potential of cortical
neural stem cells (NSCs), while inhibiting neuronal
differentiation [188, 192]. Indeed, the Id proteins are
critical for the adhesion of NSCs to their niche, as
they negatively regulate the bHLH-mediated activation
of Rap1GAP, thus preserving the GTPase activity of
Rap1, a regulator of cell adhesion. In contrast, de-
creased Id expression leads to stemness loss of NSCs
that undergo premature differentiation along the
neuronal and oligodendroglial lineages at the expense
of the astrocytic lineage [193].
The Id2 protein has been also shown to up-regulate
the bHLH transcription factor Hes1 that is important to
prevent premature neurogenesis of NSCs [194]. In con-
trast, Id2 negatively regulates NSCs self-renewal in the
developing mouse cortex [195]. Pax7, a regulator of skel-
etal muscle stem cells, inhibits the premature differenti-
ation of quiescent satellite cells by inducing Id2 and Id3
expression [196].
The Id proteins also occur in cancer stem cells, for
example in glioma stem-like cells (GSCs), where Id3
induction through the EGFR/Akt/Smad5 pathway
leads to acquirement of GSCs characteristics and
angiogenesis [197]. Id1 has been proposed to regulate
normal and malignant mammary basal stem cells
through Wnt/β-catenin/TCF/c-Myc pathway activa-
tion. Accordingly, overexpressed Id1 may lead to
oncogenic transformation of mammary stem cells,
which promotes cancer stem cell activity in breast
cancer cells [198].
Id proteins and cancer
In contrast to normal cells, cancer cells present dys-
regulated cellular pathways resulting in uncontrolled
cell division and spreading to adjacent tissue (inva-
sion) as well as to distant sites (metastasis). As the Id
proteins are involved in cellular pathways regulating
proliferation and differentiation, it is not surprising to
find them contributing to tumor-related processes
[92, 141].
Id proteins are involved in tumorigenesis and
tumor progression
Although the Id proteins do not strictly meet the classical
definition of oncogenes, as no tumor-associated mutations
in the Id genes have been observed, with the exception of
Id2 in the colorectal cancer cell line HRT-18 [82] and of
Id3 in Burkitt lymphoma [199], the fact that Id-protein
up-regulation not only is mediated by oncogenes like
Myc, Ras, and (EWS)-Ets, but it also negatively affects
tumor suppressor pathways (e. g. p53, pRb), emphasizes
their importance in tumorigenic events. Elevated Id
mRNA and protein levels have been found in many tumor
types [86, 113–115, 117–119, 200–204], in which they
have been often associated with poor prognosis.
The major role of the Id proteins in tumorigenesis is
likely to be mediated by the inhibition of bHLH tran-
scription factors and cell differentiation; however, an al-
ternative mechanism might involve a disturbing effect of
the Id proteins on the centrosomes. Centrosomes are
the primary microtubule organizing centers (MTOC) in
mitotic and post-mitotic cells. They are located adjacent
to the nucleus and are regulators of cell-cycle progres-
sion. It has been shown that a fraction of Id1, but not of
the other Id proteins, localizes to the centrosomes and
mitotic spindle poles via binding to S5a, causing abnor-
mal centrosome and centriole numbers [205–207].
These defects in the centrosome duplication presumably
contribute to genomic instability and tumor formation,
as they decrease the accuracy of mitotic replication. This
property of the Id1 protein has been attributed to the
presence of its N-terminal and HLH regions.
The role of the Id proteins in different types of cancer
is briefly described in the following subsections and
summarized in Fig. 6.
Carcinoma
Breast cancer
High levels of Id1 expression in several breast cancer cell
lines are associated with high aggressiveness and inva-
siveness [116, 208–210]. Contrarily to Id1, Id2 is down-
regulated in aggressive and invasive breast carcinomas,
while it is up-regulated in differentiated breast cancer
cells [211, 212]. Id1 expression may be induced by estro-
gen, which stimulates proliferation, whereas it may be
down-regulated by progesterone. Accordingly, cells
treated with Id1 antisense oligonucleotides proliferate
slowly upon estrogen stimulation, whereas constitutive
expression of Id1 abrogates the inhibition of breast-
cancer cell growth by progesterone, which is known to
block the growth and invasiveness of progestin-receptor
positive cancers. These results indicate that Id1 overex-
pression can be, at least in part, responsible for the de-
velopment of the hormone refractory stage of breast
cancers [97].
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Clinical studies have shown that breast cancer patients
with negative estrogen receptor status are characterized
by high Id1 expression, cell migration and poor progno-
sis [204]. In contrary, ERβ1 has been identified as a
novel binding partner and inhibitor of Id1, which sup-
ports ERβ1-induced E-cadherin expression, resulting in
the inhibition of the migration and invasion of breast
cancer cells [213].
The tumorigenic role of Id1 in breast carcinogenesis
has been associated to the inhibition of phosphatase
and tensin homolog deleted on chromosome 10
(PTEN) at the transcriptional level through p53
down-regulation. Id3-mediated PTEN inhibition re-
sults in the activation of the Akt/Wnt/TCF pathway
and in the cytosolic sequestration of p27Kip1 by its
phosphorylation [214].
Prostate cancer
It has been proposed that in androgen-dependent prostate
cancers androgen might regulate proliferation, apoptosis
and tumor suppression via Id1/Id3, Id2 and Id4 regula-
tion, respectively. In contrast, lack of this regulation in
androgen-independent cancers might lead to cell
proliferation (Id1 and Id3 up-regulation), cell survival (Id2
down-regulation) and decreased tumor suppression (Id4
down-regulation) [215–217]. Additionally, overexpression
of Id1 activates EGFR and NF-κB, resulting in aggressive
tumor progression [218, 219]. Interestingly, it has been
suggested that low levels of PSA and PSAP in aggressive
prostate cancer might be due to Id1 overexpression [220].
Furthermore, up-regulated Id1 and Id3 expression de-
creases all three cell-cycle inhibitors p16, p21, and p27,
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Fig. 6 Upstream and downstream signals of the Id proteins in some cancer types
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While Id4 is highly expressed in normal prostate epi-
thelial cells, it decreases in prostate cancer cells in a
stage-dependent manner and correlating with Id4 pro-
moter hypermethylation trough enhancer of Zeste 2
(EZH2)-dependent trimethylation of histone 3 at lysine
27 [222], which results in no Id4 expression in high-
grade cancers. Accordingly, whereas knockdown of Id4
supports the development of castration-resistant pros-
tate cancer through constitutive activation of the andro-
gen receptor [223], induced Id4 overexpression in highly
malignant prostate cancer cells leads to apoptosis, de-
creased cell proliferation, migration and reduced tumor
growth of subcutaneous xenografts [224]. These obser-
vations indicate that Id4 may act as a tumor suppressor,
likely by binding Id1-3 with consequent reactivation of
the E-protein-mediated DNA transcription [63] and/or
by positive regulation of the expression and tumor-
suppressor function of the androgen receptor [224].
However, it has been also reported that primary prostate
cancers display high levels of Id4, which has been sug-
gested to favor distant metastasis [225].
Caveolin-1, a cell membrane protein and positive regu-
lator of cell survival and metastasis in prostate cancer,
may interact with the helix-loop-helix domain of Id1. In
prostate cancer cells this interaction plays an important
role in epithelial-to-mesenchymal transition (EMT), it
increases cell migration and taxol-induced apoptosis re-
sistance through the activation of the Akt pathway [80].
Indeed, Id1 binding to caveolin-1 seems to improve the
ability of the latter to bind and inhibit PP2A, which re-
sults in Akt activation [80].
Cervical cancer
Because of the correlation of Id1 expression and human
papillomavirus (HPV)-induced cervical cancer, it is sug-
gested, that Id1 also plays a role in HPV-related cervical
carcinogenesis [226].
Thyroid cancer
In thyroid cancers the Id1 protein has been found to be
overexpressed as an early target of TGFβ. This correlates
with the development of a mesenchymal phenotype with
increased invasion capacity [227].
Nasopharyngeal cancer
Up-regulation of Id1, together with the p65 subunit of
NF-kB, has been proposed to be a marker for poor
prognosis in nasopharyngeal carcinoma. Accordingly,
inhibition of Id1 and p65 with shRNA leads to down-
regulation of MMP9 and reduction of tumor cell
migration [228].
Colon cancer
In colon cancers, which are mostly caused by mutations
in the APC (adenomatous polyposis coli) gene and/or β-
catenin genes, overexpression of Id2 has been observed
and attributed to Id2-promoter activation by up-
regulated β-catenin [114]. In primary colon cancer
samples Id1 and Id3 regulate the self-renewal of colon
cancer stem cells (CSCs) via p21. Id1/Id3 double knock-
out results in the lack of the tumor-initiating potential
and increases the sensitivity of CSCs to the chemothera-
peutic agent oxaliplatin [229].
Colorectal cancer
Colorectal cancer cells overexpressing the leukemia in-
hibitory factor (LIF) are associated with chemotherapeu-
tic resistance through down-regulation of p53. This is
mediated by Stat3 activation, which in turn up-regulates
Id1. The latter enhances MDM2 (mouse double minute
2 homolog), a key negative regulator of p53, leading to
accelerated p53 degradation [120]. Also Id3 has been
shown to promote colorectal tumorigenesis by inhibiting
p21 [230]: indeed, Id3 is a downstream target of the
Akt1/Smad5 pathway that is activated upstream by
inflammation-induced up-regulation of the Ca2+ binding
proteins calgranulin A and B (S100A8/9).
Gastric cancer
Gastric adenocarcinoma shows Id1 up-regulation,
whereas the metastatic tumors express lower Id1 levels
than the primary tumors, suggesting that Id1 may not be
determinant for gastric cancer metastasis [231].
Hepatocellular cancer (HCC)
Id1 levels have been found to be high in HCC cells,
whereas they are very low in normal liver tissues. Id1
overexpression, which is mediated by the MAPK/ERK
pathway, is associated with increased c-Myc levels: in-
deed, Id1 knockdown leads to c-Myc reduction as well
as c-Myc knockdown leads to Id1 reduction. Moreover,
Id1 may interact directly with c-Myc without inhibiting
the transcriptional activity of the latter [232].
Increased levels of Id1 have been also detected in
tissue specimens from patients with cirrhosis without
hepatocellular carcinoma and have been correlated with
higher probability to develop the tumor [233].
Pancreatic cancer
The Id proteins are implicated in the tumorigenesis of
human pancreatic cancer, a highly malignant cancer
type. Id2 is overexpressed in the cancer cells of the pan-
creatic tumor mass, contributing to cancer cell growth
that can be inhibited by Id2 antisense oligonucleotides
[234]. Also Id1 has been found to be overexpressed in
human pancreatic cancers, which is associated with
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Glioblastoma multiforme (GBM) is the highest grade
and most aggressive primary brain tumor. Id4 has been
shown to inhibit glioma invasion in vitro by inhibiting
MMP2 expression via an inhibitory interaction with
Twist1 [236], a class II bHLH transcription factor that is
highly expressed in GBM and is crucial for MMP2 ex-
pression [237, 238]. In addition, it has been shown that
Id4 expression correlates with disease-free and overall
survival of GBM patients [236]. In contrast, increased
Id1-3 protein expression correlates with tumor vascular-
ity, drug resistance and poor prognosis [239, 240].
Accordingly, Id1-silenced U87 GBM cells show signifi-
cantly decreased proliferation and invasion capacity.
Additionally, c-Myc, cyclin D1 and β-catenin expression
decreases, while E-cadherin expression increases. As E-
cadherin promotes mesenchymal-to-epithelial transition
(MET), Id1 has been predicted to regulate the metastatic
potential of GBM cells by supporting EMT [241].
High-grade glioma cells with high Id1 expression (but
no Id2 and Id3 expression) show self-renewal capacity,
whereas cells with low Id1 levels possess poor self-
renewal capacity but proliferative potential. Undifferenti-
ated low-Id1 cells are characterized by high expression
of progenitor-associated markers like Olig2. Interest-
ingly, both Id1-high and Id1-low cell types are able to
generate high-grade gliomas in mice, with faster tumor
development and higher penetrance in the case of the
low-Id1 cells. Moreover, mouse survival significantly im-
proves upon Olig2 but not Id1 deletion, suggesting that
non-self-renewal glioma cells may have high impact on
tumor growth [242]. In the case of mesenchymal gli-
omas, all three Id proteins, Id1-3, are required for main-
taining high-grade gliomas, whereas deletion of these
three genes leads to tumor regression through release of
glioma initiating cells (GICs) from the perivascular
tumor niche, which is mediated by the inhibition of the
master regulator of cell adhesion Rap1. Therefore, the
interaction of GICs with endothelial cells is disrupted,
which results in their loss of self-renewal and tumor-
forming capacity [243].
Recently, it has been shown that cancer stem cells and
glioma aggressiveness are supported by a mechanism
based on Id2 and the hypoxia-inducible factor 2α
(HIF2α). Indeed, under hypoxia the unphosphorylated
state of Id2 at Thr-27 is maintained upon inactivation of
tyrosine-phosphorylation-regulated kinase 1 (Dyrk1).
Unphosphorylated Id2 is able to bind the VHL-elongin-
C complex, thus disrupting the ubiquitin-ligase complex
VCB-Cul2 (pVHL-elongin C-elongin B-Cullin-2), which
results in HIF2α stabilization by inhibition of its ubiqui-
tination. This, in turn, leads to Id2 up-regulation, as
HIF2α is a positive transcriptional regulator of the Id2
gene [82].
Neuroblastoma
In neuroblastoma, an extracranial cancer mostly oc-
curring in infants and children and characterized by
the amplification and overexpression of the oncogene
N-Myc (neuronal Myc) [244], Id2 is transcriptionally
activated by Myc oncoproteins [115]. In turn, overex-
pression of Id2 abrogates pRb-induced cell-cycle ar-
rest by direct binding to pRb [115, 141, 245].
However, whether a correlation exists between N-Myc
and Id2 gene/protein expression in neuroblastoma
[246–250], or if the Myc action in vivo is mediated
by Id2 in other cancer types like epidermal neoplasia
[251] and lymphomagenesis [252] are still controver-
sial and would need further investigation [141].
The four-and-a-half LIM-only protein 2 (FHL2) is able
to interact with all four Id proteins through a relatively
conserved region within the N-terminal Id protein do-
mains (C/S-L-S/A-E/D—S-L/V-A/G-I/G-S/A-R/A). After
retinoic acid induced differentiation of neuroblastoma
cells, FHL2 expression increases and counteracts the in-
hibitory effects of the Id proteins on E47, resulting in re-
stored E47 induced transcription. Therefore, FHL2 is
proposed to be a repressor of the oncogenic activity of Id2
in neuroblastoma [81].
Neuroblastoma cells are able to undergo reversible
adaptive plasticity to survive and escape radio- or
chemotherapy. One phenotype is highly proliferative and
anchorage dependent (AD), the other is slow growing,
anoikis-resistant and anchorage independent (AI) [253].
In the proliferating AD cells Id2 has been found to be
20-fold more expressed than in the AI cells (together
with N-Myc, which would support Id2 being an effector
of N-Myc [115, 245]), and it is suggested to support pro-
liferation by antagonizing the TGFβ/Smad2/3 pathway.
Accordingly, Id2 down-regulation in AD cells activates
the TGFβ pathway, resulting, however, not only in de-
creased proliferation and induction of apoptosis, but also
in activation of anoikis-resistant pathways, similar to
cells with the AI phenotype. Instead, overexpressed Id2
in AI cells leads to the proliferative AD phenotype,
allowing the cells to survive unfavorable and stressful
conditions. These observations suggest that Id2 plays a
key role in reversible adaptive plasticity in neuroblast-
oma cells. Simultaneous targeting of the AD and AI phe-
notypes by using the chemotherapy agents doxorubicin
and metformin and of the pathways responsible for re-
versible adaptive plasticity with LY2109761, a TGFβ re-
ceptor inhibitor, and sorafenib, a multi-kinase inhibitor,
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results in decreased tumor growth and prolonged sur-
vival in established mouse neuroblastoma tumors [254].
Medulloblastoma
In medulloblastoma the Id2 and Id3 proteins are overex-
pressed and promote tumor cell proliferation, whereas
the Id1 protein has been found to be expressed in the
tumor vessels, thus promoting tumor angiogenesis. In
contrast, Id4 has been detected neither in normal cere-
bellum nor in tumor cells [255].
Leukemia
Acute myeloid leukemia (AML)
Id2 and Id3 show different expression patterns and
subcellular localization in acute leukemia subtypes:
for example, AML is characterized by higher Id2 and
Id3 expression than acute lymphoblastic leukemia
(ALL) [256].
Overexpressed Id1 or Id3 are able to immortalize
growth factor-dependent hematopoietic progenitors
resulting in cells with an acute myeloid leukemia
(AML)-like morphology and decreased p15INK, p16INK4,
p19ARF and p21Cip1 in vitro. In vivo Id1 overexpression
leads to lethal myeloproliferative disease [257]. Id1 and
Id2 mRNA levels are associated with AML, whereby pa-
tients with increasing Id1 levels correlate with poor clin-
ical outcome. Microarray analysis suggests that Id1 and
Id2 gene expression might be induced downstream of
multiple signal transduction pathways of mutationally
activated oncogenic tyrosine kinases like FLT3, TEL-
ABL, BCR-ABL and PDGFRB [119, 258].
Down-regulated Id2 and up-regulated E2-2 have been
observed in mixed lineage leukemia (MLL)-rearranged
AML, which supports leukemia stem cell potential and
confer poor prognosis. This suggests that Id2 might have
a tumor suppressor role in MLL-rearranged AML as
well as in t(8;21) AML [259].
Id4 methylation plays an important role in disease pro-
gression in patients with myelodysplastic syndrome
(MDS) that is a myeloid hematopoietic malignant dis-
order with high susceptibility to transform into AML.
High levels of Id4 methylation have been correlated with
decreased survival [260].
Chronic lymphocytic leukemia (CLL)
Id2 and Id3 support survival of CLL cells, probably by
inhibiting pro-apoptotic pathways. Moreover, the CLL
cells with high Id3 and, to a lesser extent, Id2 levels dis-
play high chemoresistance [261].
Chronic myeloid leukemia (CML)
In CML Id4-promoter methylation increases during dis-
ease progression from the chronic to the accelerated
phase and blast crisis [262]. The crucial role of Id4 has
been proven with haploid loss of Id4 in non-transformed
TCL1-positive B cells, leading to enhanced B-cell prolif-
eration and decrease in dexamethasone-mediated apop-
tosis [263].
Lymphoma
Id2 is overexpressed in Hodgkin lymphoma tumor cells
and suppresses the expression of B cell specific genes
[264]. Id4 methylation has been found to be high in
lymphoma tissues, whereas no methylation has been de-
tected in control tissues. Moreover, high Id4 methylation
correlates with decreased survival [265, 266]. In Burkitt
lymphoma missense mutations of Id3 have been found,
which lead to mutated HLH domain and altered ability
of Id3 to inhibit TCF3 and/or TCF4 [199]. Accordingly,
Id3 mutations have been observed in more than 50% of
all Burkitt lymphomas, and the presence of Id3 and/or
TCF3 mutations has been detected in 70% of sporadic
Burkitt lymphomas. The Id3 destructive and/or the
TCF3 activating mutations lead to TCF3 activated tran-
scription resulting in pro-survival phosphoinositide 3-
kinase (PI3K) signaling [267]. These results indicate that
Id3 inactivating mutations, together with IG-Myc trans-
location, are characteristic properties of Burkitt lymph-
oma pathogenesis [199].
The role of the Id1 isoform in cancer
While there are many studies about the role of Id1 in
cancer development and progression, much less is
known about the Id1 isoform generated by alternative
splicing. In contrast to the crucial role of Id1 in cancer,
overexpression of its isoform in lung and prostate cancer
cells leads to cell-growth arrest, tumor shrinkage, im-
paired angiogenesis and sensitization to radiotherapy-
induced cell death [36]. Furthermore, unlike Id1 that
promotes cell proliferation, its isoform causes a cancer
stem cell-like phenotype and promotes its self-renewal.
This would support a role of Id1 and its isoform in
tumor initiation by promoting self-renewal properties by
the spliced Id1 variant and, subsequently, proliferation
by canonical Id1 [35].
The role of Id4 in cancer
In various human tumor types such as acute and
chronic leukemia [268], different malignant lymph-
omas [265, 266, 269], colorectal carcinoma [270],
breast cancer [271] and gastric carcinoma [272], the
tumor suppressor activity of Id4 is abrogated through
epigenetic inactivation of its promoter by methylation
during cancer development. These findings would
suggest that Id4 gene methylation degree might be
used as a tumor marker. However, the role of Id4 in
breast cancer remains controversial [273]: indeed, Id4
has been detected in breast cancer cells expressing
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p53 mutants, promoting tumor neo-angiogenesis
[111], as well as in tamoxifen-refractory breast cancer,
thus supporting chemoresistance [274].
The role of the Id proteins in cancer metabolism
A crucial event of cancer development and progression
is the metabolic reprogramming of cancer cells to cover
their high glucose requirements. This takes place under
control of oncogenic signaling pathways and several mu-
tations occurring in cancer [275, 276]. For example, c-
Myc seems to be one of the main regulators of aerobic
glycolysis and glutaminolysis [277]. It has been shown
that Id1 and c-Myc positively regulate each other’s ex-
pression in hepatocellular carcinoma cells and promote
c-Myc-mediated glycolysis under aerobic conditions. In-
stead, under anaerobic conditions glycolysis is promoted
by the hypoxia-inducible factor 1α (HIF1α) that recruits
Mxi1, a transcriptional suppressor of Id1 and c-Myc,
thus leading to down-regulation of Id1 and c-Myc ex-
pression [232].
The role of the Id proteins in tumor angiogenesis
and metastasis
Prerequisite for tumor progression and metastasis is a
sufficient blood supply guaranteed by the formation
of new blood vessels (tumor angiogenesis). The initi-
ation of angiogenesis in tumors is triggered by the
up-regulation of VEGF that promotes the exponential
growth of the tumor. Like in neoangiogenesis during
normal development, the Id proteins play a role also
in tumor neoangiogenesis [149, 185]. Accordingly, Id1
+/− Id3−/− mice fail to grow tumors due to poor
vascularization and necrosis [149].
Matrix metalloproteinases (MMPs) are zinc-dependent
endopeptidases that mediate membrane degradation and
cell migration. Id1, Id2 and Id3 may increase MMP gene
expression, leading to tumor cell invasion. High levels of
Id1 and the membrane-type 1-MMP (MT1-MMP) [209]
or MMP1 [278] have been associated to breast cancer
metastasis. In melanoma, the Id1-induced up-regulation
of MMP2 is mediated by the adhesion molecule
MUC18. MUC18 positively regulates Id1 expression
through the modulation of ATF3, contributing to melan-
oma metastasis. Indeed, silencing of MUC18 leads to in-
creased ATF3 binding to the Id1 promoter, which results
in Id1 down-regulation [279].
The zinc-finger protein KLF17 is a metastasis suppres-
sor by inhibition of Id1 transcription upon binding to its
promoter region. KFL17 is significantly down-regulated
in primary human breast cancer samples. Therefore, its
suppression leads to Id1 induction, which might pro-
mote primary tumor vascularization via VEGF produc-
tion, breast cancer cell invasion and EMT [280]. Id2 also
seems to play a crucial role in tumor cell migration and
invasion: indeed, c-Myc up-regulation and subsequent
Id2 overexpression in highly metastatic human tumor
cell lines lead to down-regulation of semaphorin 3 F
(SEMA3F) that is a potent metastasis inhibitor and a
direct target gene of the E47/Id2 pathway [281, 282].
In colorectal cancer it has been shown that hypoxia, a
common feature of solid tumors, may increase the can-
cer stem cells (CSCs) subpopulations as well as promote
cancer metastasis. The proposed mechanism relies on
the hypoxia-mediated activation of the Wnt/β-catenin
signaling that leads to Id2 overexpression that, in turn,
induces a CSCs phenotype and expression of MMP2 and
MMP9 responsible for increased cell migration [283].
There is growing evidence that phenotypic plasticity,
in particular the epithelia-to-mesenchymal and
mesenchymal-to-epithelial transition switch (EMT-
MET), is required for effective cancer metastasis [284].
In breast cancer Id1 plays a crucial role in phenotype
switching during lung metastasis [285, 286]. TGFβ-
induced overexpression of Id1 is necessary not only to
obtain tumor-initiating cells at the primary site, but also
to switch the EMT phenotype, which is induced by the
zinc finger transcription factor Snail at the primary site,
back to the MET one at the colonization site. It has been
shown that Id1 may induce the EMT-to-MET switch at
the distant site by antagonizing Twist1, but not at the
primary site, where the EMT phenotype is maintained
by the presence of Snail [285].
Id proteins and chemotherapeutic drug resistance
Chemotherapeutic drugs function by inducing cell death
in cancer cells. A limitation of chemotherapy is the drug
resistance that is associated with a more aggressive can-
cer disease and the resistance to further chemotherapeu-
tic treatments. Factors positively affecting multi-drug
resistance include up-regulation of the multi-drug trans-
porter P-glycoprotein [287], and of the inhibitor of apop-
tosis Bcl2 [288], as well as activation of the Raf-1/MAPK
[289] and NF-κB [290] pathways, and inactivation of the
c-Jun N-terminal kinase (JNK) pathway [291]. Based on
the fact that Id1 can activate the Raf-1/MAPK and NF-
κB pathways [140, 292], a role of Id1 in the development
of drug resistance has been suggested.
In prostate cancer Bcl3 is overexpressed via IL6, lead-
ing to the up-regulation of Id1 and Id2, and inducing re-
sistance against anticancer drugs. Accordingly, Bcl3
knockdown results in decreased Id1 and Id2 expression,
with tumor cells becoming more sensitive to chemother-
apeutic drug-induced apoptosis [118]. REIC/Dickkopf-3
(Dkk-3) is a tumor suppressor that is reduced in numer-
ous human cancers. Overexpression of REIC/Dkk-3 in
malignant mesothelioma (MM) down-regulates Id1 ex-
pression via activation of ATF3 and Smad, resulting in
enhanced JNK phosphorylation and REIC/Dkk-3-
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induced apoptosis [293]. In contrast, ectopic Id1 expres-
sion induces resistance to taxol treatment in breast,
prostate and nasopharyngeal carcinoma cells [294–296].
Hence, increased sensitivity to taxol-mediated JNK acti-
vation and apoptosis in prostate cancer could be reached
by using small RNA interfering technology to down-
regulate Id1 [297].
Besides resistance against taxol, Id1 seems to induce
resistance also against other antitumor agents including
doxorubicin, cyclophosphamide [298] and epirubicin
[299], which suggests that Id1 promotes cell survival by
acting as universal antiapoptotic factor [300]. These re-
sults provide a linkage between up-regulation of the Id
proteins and poor prognosis and severity of some human
cancer types.
Id1 overexpression shows not only high correlation with
tumor invasion, metastasis and poor prognosis in esopha-
geal squamous cell carcinoma (ESCC), but it also plays a
crucial role in the resistance to the anticancer drugs eto-
poside [301] and 5-fluorouracil (5-FU) [302]: indeed, eto-
poside enhances c-Jun/c-Fos expression that leads to Id1
gene transcription and expression, resulting in inhibition
of apoptosis [301]. 5-FU chemoresistance is accompanied
by up-regulated expression of Id1, insulin-like growth fac-
tor 2 (IGF2) and the transcription factor E2F1. Id1 inhibits
E2F1 degradation by binding to Cdc20. In turn, E2F1
binds to the IGF2 promoter and activates its transcription.
IGF2 increases phosphorylated-Akt and its downstream
target thymidylate synthase, which abolishes 5-FU-
induced apoptosis [302].
Treatment of hepatocellular carcinoma cells with the
antitumor drug sodium butyrate (NaB), a histone deace-
tylase (HDAC) inhibitor, has shown dependency from
the Id2 expression: indeed, NaB-mediated induction of
anti-apoptotic Bcl2 is inhibited by Id2 knockdown but it
is supported by Id2 overexpression. Therefore, the Id2
level has been suggested to serve as prognostic marker
for clinical response to HDAC inhibitors [303].
Glioma stem cells (GSCs) are relatively resistant to
chemotherapy and irradiation. Id4 has been shown to
suppress miR-9 and induce SOX2. Enhanced SOX2 ex-
pression leads to induction of ATP-binding cassette
(ABC) transporters 3 and 6, resulting in chemoresistance
of GSCs. Furthermore, elevated SOX2 expression dedif-
ferentiates astrocytes and glioma cells to GSCs [304].
The Id proteins as therapeutic targets
Cancer diseases are one of the most frequent causes
of death in developed countries and require the con-
stant research of novel, potent anti-tumor therapeu-
tics. The Id proteins represent interesting targets for
such purpose, as they are involved in cellular key
events related both to tumorigenesis and cancer
progression [149, 201, 305].
Different approaches to reduce aberrant Id-protein
levels and restore differentiation of hyperproliferative
cells have been successfully applied. For example, by
treating human metastatic breast cancer cells with an
Id1 antisense oligonucleotide not only Id1 decreases, but
also MT1-MMP. Therefore, the significantly reduced
breast cancer metastasis to the lung might be a result of
reduced MT1-MMP-mediated invasiveness [209].
Furthermore, targeting Id1 with Id1-siRNA in adenoid
cystic carcinoma (ACCM) mouse models inhibits tumor
growth, reduces tumor cell proliferation/invasion and in-
duces apoptosis [306].
An Id1 antisense oligonucleotide conjugated to a pep-
tide that addresses tumor neovessels specifically has
been used to decrease the growth rate of breast tumors
and the highly aggressive Lewis Lung carcinomas
(LLCs). Moreover, the metastatic growth of LLCs could
be delayed. This antitumor effect enhances upon com-
bination with the Hsp90 inhibitor 17-AAG [307].
MicroRNAs (miRNAs) are a class of small, non-
coding RNAs that regulate gene expression and
differentiation by interacting with mRNAs. Retinoic
acid-induced up-regulation of two miRNAs (miR-9
and miR-103) during neuroblastoma cell differenti-
ation inhibits Id2 expression and cell growth. There-
fore, these two miRNAs may have tumor suppressive
properties in several neural tumors [308].
In metastatic breast cancer, glioblastoma and saliv-
ary gland cancer cannabidiol, a low toxic cannanbi-
noid, has been shown to reduce Id1 expression,
resulting in less tumor growth, aggressiveness and
metastasis [309–311].
The influence of MK615, an extract from the Japanese
apricot “Prunus mume” known for antitumorigenic and
antiinflammatory effects, has been studied in human
malignant melanoma cells: MK615 reduces Id1 expres-
sion and, therefore, cell growth through the inhibition of
the ERK1/2 pathway [312].
Curcumin significantly down-regulates mRNA and
protein levels of Id1 in prostate cancer cells and xeno-
grafted tumors, which is accompanied by induction of
apoptosis and tumor growth suppression [313].
Berberine, an isoquinoline alkaloid present in different
herbs, including barberry, has shown anti-proliferative
and anti-metastatic effects in hepatocellular carcinoma
mice via Id1 down-regulation at the transcriptional level.
Indeed, berberine may inhibits the Id1 promoter activity,
resulting in suppression of cellular growth, invasiveness
and VEGF secretion [314].
An arabinogalactan polysaccharide from the Panax
notoginseng (RN1) has been able to inhibit microvessel
formation in pancreatic cancer-cell xenograft tumors in
nude mice through the inhibition of BMP2/Smad-in-
duced Id1 expression [315].
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2-Methoxyestradiol, a metabolite of 17-β-estradiol,
may inhibit angiogenesis and reduce tumor growth at
late stages through enhanced apoptosis. This correlates
with the inhibition of Id1 in mouse and human breast
cancer cell lines [316]. In gastric cancer cells, Id1 could
be dose-dependently decreased by sulindac sulfide, a
non-steroidal anti-inflammatory drug [317]. Further-
more, treatment with epigallocatechin-3-gallate, a cat-
echin from tea, down-regulates Id1 mRNA and protein
in poorly differentiated AGS gastric cancer cells [318].
TGFβ, Id1 and CD44 regulate glioma stem cells, which
are responsible for glioblastoma initiation, relapse, and
therapeutic resistance. Treating patient-derived glioblast-
oma specimens with LY2109761, a TGFβ receptor type I
and II dual antagonist, leads to the reduction of
CD44high/Id1high glioma stem cells, thus preventing
tumor initiation and recurrence [109].
USP1 is up-regulated by PDGF via E2F. This signal
stabilizes Id2 expression that is crucial for glioma sur-
vival. Pimozide, an anti-psychotic drug and USP1 in-
hibitor, might have therapeutic activity in patients
with proneural PDGF-driven glioblastoma. Indeed,
pimozide suppresses Id2 expression and reduces
tumor growth [319].
Furthermore, chemosensitivity of human U87 GBM
cells may be enhanced by silencing Id2. Indeed, the anti-
proliferative effect of the anti-tumor agents semustine,
teniposide and temozolomide is higher in Id2-silenced
cells than in Id2-expressing cells. As Id2-silenced cells
express higher levels of caspase-3, it is likely that their
increased chemosensitivity is due to the up-regulation of
pro-apoptotic pathways [240].
Src tyrosine kinase is suggested to promote tumor ag-
gressiveness through BMP2-induced Id1 expression. Ac-
cordingly, Id1 levels are reduced in breast, prostate, lung
and colon cancer cell lines treated with the small-
molecule Src inhibitor AZD0530 [320].
PI3K/Akt signaling is a downstream component of Id1
and promotes osteosarcoma progression. Accordingly,
the PI3K inhibitor LY294002 decreases Id1-induced
osteosarcoma tumor growth [321].
Inhibition of BMP signaling by the small molecule
DMH2 that binds BMP type I receptors has led to de-
crease in Id proteins and suppression of growth of can-
cer cells expressing stem cell markers [322].
The DNA-damaging agents camptothecin and adria-
mycin are able to inhibit Id1 expression trough wild-
type p53 induced DEC1 that binds to the Id1 promoter
and represses its transcription [138].
Recently, a small molecule (AGX51) that directly tar-
gets the Id proteins has been discovered, which blocks
tumor angiogenesis and is currently in the preclinical
phase for drug development [323, 324]. In addition,
peptide-based molecules have been developed to bind
the Id proteins and inhibit their function. A peptide
aptamer (Id1/Id3-PA7) has been developed, which in-
duces cell cycle arrest and apoptosis in ovarian and breast
cancer cells by inhibition of Id1 and Id3 [325, 326]. A
modified HEB HLH domain has been shown to interfere
with and inhibit Id2 in human neuroblastoma cells. This
has led to the activation of the cell-cycle inhibitor p27Kip1
with induction of growth arrest and neural differentiation
[327, 328]. Short peptides based on MyoD [329] or Id [57,
330] HLH sequences have been designed, which bind the
Id proteins in the low-micromolar range and are able to
inhibit proliferation of cancer cells and of a vascular
smooth muscle cell phenotype.
A T-cell mediated vaccine approach has been recently
tested in mouse neuroblastoma. Id2-knockdown neuro-
blastoma cells (Id2kd-Neuro2a) have shown to be
immunogenic. These cells do not grow in immune-
competent mice that even develop immunity against wild-
type neuroblastoma cells. In contrast, Id2kd-Neuro2a cells
grow aggressively in immune-compromised mice. In com-
bination with the use of an antibody against the cytotoxic
T lymphocyte antigen-4 (CTLA-4), an inhibitor of T-cell
responses, vaccination with Id2kd-Neuro2a cells of mice
bearing established neuroblastoma tumors has been
shown not only to suppress the tumor growth but also to
eradicate the tumor itself [331].
A nanoparticle-based approach has been recently used
to deliver recombinant Id4 protein as a biotherapeutic
agent into prostate cancer cells or into prostate cancers
in mice. Indeed, Id4 expression is epigenetically silenced
in prostate cancer, whereas its ectopic expression sup-
presses the cancer phenotype. Accordingly, delivery of
Id4 encapsulated in biodegradable polycaprolactone/
maltodextrin nanoparticles leads to increased apoptosis,
decreased proliferation and colony formation. In vivo
the Id4-nanoparticle approach has been shown to be
more efficient than the administration of docetaxel in re-
ducing the tumor volume [332].
Conclusions
The Id proteins exert their function by interacting with
and modulating key regulators of the cell cycle. The four
members of the Id family show distinct expression pat-
terns and, despite the high homology of their HLH do-
mains, display different protein-protein interaction
preferences both under physiological and pathological
conditions. This suggests that, on the one hand, the
structure of the Id HLH domain is fine-tuned and that,
on the other hand, the non-conserved N-terminal and
C-terminal domains are determinant for the specific
protein binding profile of each Id protein. Although the
main mechanism of the Id proteins rely on the direct
interaction and modulation of bHLH factors, the data
reported in the literature and partly summarized in this
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review clearly show that the mode of action of these four
small proteins is highly complex. This is due to their
ability to interact with a multiplicity of proteins that be-
long to different families and affect different cellular
pathways. Strikingly, such functional diversity reflects
the structural flexibility of the Id proteins that, in fact,
contain high degree of disorder. Obviously, this signifi-
cant structural and functional diversity makes the Id
proteins a challenging topic of research; however, the
successful work done so far encourages to continue the
exploration of the biology and structure of these intri-
guing protein regulators, with the aim to understand
and solve controversial data, to answer still open ques-
tions, to further validate them as targets for tumor diag-
nostics and therapy, and to develop drug-like molecules
for their detection and inhibition in vivo.
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